Literature DB >> 23273871

The Rasch-built Pompe-specific activity (R-PAct) scale.

N A M E van der Beek1, M L C Hagemans, A T van der Ploeg, P A van Doorn, I S J Merkies.   

Abstract

We constructed a patient-based interval scale using Rasch analysis, specifically suited to quantify the effects of Pompe disease on patient's ability to carry out daily life activities and their social participation: Rasch-built Pompe-specific Activity scale. Between July 2005 and April 2011, 186 patients aged 16 or older, participated to develop this scale. External construct validity was determined through correlations with the MRC sumscore and Rotterdam Handicap Scale. Furthermore, test-retest reliability was determined in a subgroup of 44 patients. Finally, individual person-level responsiveness was used to determine the proportion of patients demonstrating significant improvement or deterioration during their natural disease course, or during treatment with enzyme replacement therapy. Of the original 49 items, 31 were removed after investigation of model fit, internal reliability, threshold examination, item bias, and local dependency. The remaining 18 items were ordered on a linearly weighted scale and demonstrated good discriminative ability (Person Separation Index 0.96), external construct validity (intraclass correlation coefficient (ICC) for MRC sumscore 0.82, and for the Rotterdam handicap scale 0.86), reliability of person's location (ability comparison: ICC 0.95), and responsiveness. We therefore conclude that the R-PAct scale enables us to accurately detect limitations in activities and social participation throughout the entire disease spectrum in patients with Pompe disease.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23273871     DOI: 10.1016/j.nmd.2012.10.024

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  13 in total

1.  Ten years of the international Pompe survey: patient reported outcomes as a reliable tool for studying treated and untreated children and adults with non-classic Pompe disease.

Authors:  J C van der Meijden; D Güngör; M E Kruijshaar; A D J Muir; H A Broekgaarden; A T van der Ploeg
Journal:  J Inherit Metab Dis       Date:  2014-08-12       Impact factor: 4.982

2. 

Authors:  Harrison N Jones; Maragatha Kuchibhatla; Kelly D Crisp; Lisa D Hobson Webb; Laura Case; Milisa T Batten; Jill A Marcus; Richard M Kravitz; Priya S Kishnani
Journal:  Mol Genet Metab       Date:  2019-05-08       Impact factor: 4.797

3.  Development and Construct Validity of the Work Instability Scale for People With Common Mental Disorders in a Sample of Depressed and Anxious Workers: A Rasch Analysis.

Authors:  Louise Danielsson; Robin Fornazar; Kristina Holmgren; Åsa Lundgren Nilsson; Gunnel Hensing
Journal:  Rehabil Process Outcome       Date:  2020-07-14

4.  Reconstructing the Rasch-Built Myotonic Dystrophy Type 1 Activity and Participation Scale.

Authors:  Mieke C E Hermans; Janneke G J Hoeijmakers; Catharina G Faber; Ingemar S J Merkies
Journal:  PLoS One       Date:  2015-10-20       Impact factor: 3.240

Review 5.  The clinical relevance of outcomes used in late-onset Pompe disease: can we do better?

Authors:  Robin Lachmann; Benedikt Schoser
Journal:  Orphanet J Rare Dis       Date:  2013-10-12       Impact factor: 4.123

Review 6.  Patient reported outcome measures in rare diseases: a narrative review.

Authors:  Anita Slade; Fatima Isa; Derek Kyte; Tanya Pankhurst; Larissa Kerecuk; James Ferguson; Graham Lipkin; Melanie Calvert
Journal:  Orphanet J Rare Dis       Date:  2018-04-23       Impact factor: 4.123

7.  Positive association between physical outcomes and patient-reported outcomes in late-onset Pompe disease: a cross sectional study.

Authors:  Meng Yuan; Eleni-Rosalina Andrinopoulou; Michelle E Kruijshaar; Aglina Lika; Laurike Harlaar; Ans T van der Ploeg; Dimitris Rizopoulos; Nadine A M E van der Beek
Journal:  Orphanet J Rare Dis       Date:  2020-09-03       Impact factor: 4.123

8.  The ACE I/D polymorphism does not explain heterogeneity of natural course and response to enzyme replacement therapy in Pompe disease.

Authors:  Esther Kuperus; Jan C van der Meijden; Stijn L M In 't Groen; Marian A Kroos; Marianne Hoogeveen-Westerveld; Dimitris Rizopoulos; Monica Yasmin Nino Martinez; Michelle E Kruijshaar; Pieter A van Doorn; Nadine A M E van der Beek; Ans T van der Ploeg; W W M Pim Pijnappel
Journal:  PLoS One       Date:  2018-12-07       Impact factor: 3.240

9.  Quality of life and participation in daily life of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow-up.

Authors:  Deniz Güngör; Michelle E Kruijshaar; Iris Plug; Dimitris Rizopoulos; Tim A Kanters; Stephan C A Wens; Arnold J J Reuser; Pieter A van Doorn; Ans T van der Ploeg
Journal:  J Inherit Metab Dis       Date:  2015-11-03       Impact factor: 4.982

10.  Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures.

Authors:  P Vanherpe; S Fieuws; A D'Hondt; C Bleyenheuft; P Demaerel; J De Bleecker; P Van den Bergh; J Baets; G Remiche; K Verhoeven; S Delstanche; M Toussaint; B Buyse; P Van Damme; C E Depuydt; K G Claeys
Journal:  Orphanet J Rare Dis       Date:  2020-04-05       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.